Contacts, documents and full notice history are available with a subscription.
Special Notice NONE Expired 1 notice 1 document

6505--Pluvicto and Lutathera | VA GLA 36C26225Q1321

Solicitation 36C26225Q1321 Copied Notice ID 3cbdc52d9d234b67a27f70468c7b480b Copied VETERANS AFFAIRS, DEPARTMENT OF — 262-NETWORK CONTRACT OFFICE 22 (36C262)
SAM.gov
Posted
Aug 05, 2025
Deadline
Aug 15, 2025
Set-aside
NONE
NAICS
325412
PSC
6505

Summary

AI-generated · Aug 24, 2025

The Department of Veterans Affairs intends to award a sole-source delivery order to Novartis Pharmaceuticals Corporation for two radiopharmaceuticals: Pluvicto Lutetium-177 vipivotide tetramer (27 mCi/mL) and Lutathera Lutetium-177 DOTATATE, in quantities of 105 and 10 units respectively, to support treatment of advanced prostate cancer and neuroendocrine tumors. This action falls under FAR Part 8 with an 8.405-6(a)(1)(B) “Only One Available Source” justification, and these items were previously awarded under contract 36F79720D0180 issued on 7/30/2020.

Interested, responsible firms may submit capabilities statements demonstrating they can provide the same items and that competition would be advantageous. Responses must be in writing to Hestia Sim (email provided) with the subject line “RESPONSE TO INTENT TO SOLE SOURCE Pluvicto and Lutathera,” and are due by 10:00 AM Pacific Time on August 15, 2025. This notice is informational only and not a solicitation; no documents will be issued, and no awards will be made on the basis of unsolicited offers.

NOTICE OF INTENT TO SOLE SOURCE This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. The Department of Veterans Affairs, Network Contracting Office (NCO) 22, located at 4811 Airport Plaza Drive, Long Beach, CA is issuing this Notice of Intent (NOI) to inform industry contractors of the Government s intent to execute a Sole Source Delivery Order under FAR Part 8, specifically FAR Part 8.405-6(a)(1)(B), Only One Available Source. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees. The intended contractor is Novartis Pharmaceuticals Corporation located at 59 Route 10, East Handover, NJ 07936. Place of Performance is the VA Greater Los Angeles Healthcare System located at 11301 Wilshire Blvd, Los Angeles, CA 90073. VA Greater Los Angeles Nuclear Medicine Service intends to purchase PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML and LUTATHERA LUTETIUM LU 177 DOTATATE in quantities listed below: NDC# Contract Description Qty UOM 69488-0010-61 36F79720D0180 PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML 105 EA 69488-0003-01 36F79720D0180 LUTATHERA LUTETIUM LU 177 DOTATATE 10 EA VA Greater Los Angele Healthcare System Nuclear Medicine Service requires Pluvicto to treat advance prostate cancer and Lutathera to treat neuroendocrine tumor therapy. Radiopharmaceuticals requested were awarded to Novartis Pharmaceuticals Corporations on 7/30/2020 under contract 36F79720D0180. This notice of intent is neither a formal solicitation nor a request for competitive proposals. No solicitation document is available and telephone requests will not be honored. No award will be made on the basis of unsolicited quotations or offers received in response to this notice. Any response to this notice must show clear and compelling evidence that the responding company can provide the same items/services, and that competition will be advantageous to the Government. The intent of this synopsis is for informational purposes only. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this action based on this notice is solely within the discretion of the Government. All inquiries and concerns must be addressed in writing via e-mail to Hestia Sim, Hestia.Sim@va.gov with RESPONSE TO INTENT TO SOLE SOURCE Pluvicto and Lutathera in the subject line. All interested parties who are responsible, certified, and capable may identify their interest and may submit a capabilities statement no later than 10:00 AM Pacific Local Time August 15, 2025, to the above-mentioned point of contact. The interested parties bear full responsibility to ensure complete transmission and timely receipt. The Department of Veterans Affairs will NOT be responsible for any costs incurred by interested parties in responding to this notice of intent.

From Special Notice posted on Aug 05, 2025

Notice history

1
  1. Special Notice LATEST Posted Aug 05, 2025

Details

Solicitation number 36C26225Q1321
Notice ID 3cbdc52d9d234b67a27f70468c7b480b
Notice type Special Notice
Product / Service (PSC) 6505
NAICS 325412
Set-aside No Set aside used
Place of performance Los Angeles, California
Archive date Sep 05, 2025

Award Information

Not yet awarded

Documents

1
View on SAM.gov

Contacts

primary
Hestia Sim

Email

Agency

VETERANS AFFAIRS, DEPARTMENT OF
VETERANS AFFAIRS, DEPARTMENT OF
262-NETWORK CONTRACT OFFICE 22 (36C262)

Place of Performance

Los Angeles, California 90073
USA

Dates

Posted Aug 05, 2025 1 year ago
Last Updated Aug 06, 2026 1 day ago
Due Aug 15, 2025 11 months ago